Mechanism of action of progesterone antagonists

Experimental Biology and Medicine

Volumn 227, Issue 11, 2002, Pages 969-980

  Leonhardt, Susan A ^a   Edwards, Dean P ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Progesterone; Progesterone receptor; RU486, nonsteroidal antagonists; Steroidal antagonists

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; 8 BROMO CYCLIC AMP; ANDROGEN RECEPTOR; ANTIGESTAGEN; CP 8400; CP 8401; DNA; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LG 001447; LG 100127; LG 120753; LG 120830; MIFEPRISTONE; ONAPRISTONE; ORG 31806; ORG 33628; PF 1092C; PROMEGESTONE; PYRIDAZINE DERIVATIVE; RTI 012; RTI 022; RWJ 26329; TETRAHYDROPYRIDAZINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; DIMERIZATION; DNA BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENDOMETRIOSIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HORMONE RECEPTOR INTERACTION; HUMAN; PREGNANCY; PREGNANCY TERMINATION; SHORT SURVEY; SIGNAL TRANSDUCTION; UTERUS MYOMA;

EID: 0036917921     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222701104     Document Type: Short Survey

References (74)

1. Spitz IM, Croxatto HB, Robbins A. ANTIPROGESTINS: Mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 36:47-81, 1996.
2. Cadepond F, Ulmann A, Baulieu E-E. RU486 (Mifepristone): Mechanisms of action and clinical uses. Annu Rev Med 48:129-156, 1997.
3. Baulieu E-E. Contragestion and other clinical applications of RU486, an antiprogesterone at the receptor. Science 245:1351-1357, 1989.
4. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141, 2000.
5. Edwards DP. Coregulatory proteins in nuclear receptor action. Vitam Horm 55:165-218, 1999.
6. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-474, 2002.
7. Bain DL, Franden MA, McManaman JL, Takimoto GS, Horwitz KB. The N-terminal region of the human progesterone A-receptor. J Biol Chem 275:7313-7320, 2000.
8. Bain DL, Franden MA, McManaman JL, Takimoto GS, Horwitz KB. The N-terminal region of human progesterone N-receptors. J Biol Chem 276:23825-23831, 2001.
9. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614, 1990.
10. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209-5218, 2002.
11. Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: Two functionally different transcription factors encoded by a single gene. Rec Prog Horm Res 54:291-313, 1999.
12. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 8:1347-1360, 1994.
13. Conneely OM, Lydon JP. Progesterone receptors in reproduction: Functional impact of the A and B isoforms. Steroids 65:571-577, 2000.
14. Conneely OM, Mulac-Jericevic B, Lydon JP, DeMayo FJ. Reproductive functions of the progesterone receptor isoforms: Lessons from knock-out mice. Mol Cell Endocrinol 179:97-103, 2001.
15. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E. Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci USA 95:696-701, 1998.
16. Cheung J, Smith DF. Molecular chaperone interactions with steroid receptors: An update. Mol Endocrinol 14:939-946, 2000.
17. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai M-J, Edwards DP, O'Malley BW. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273:12101-12108, 1998.
18. Shiau A, Barstad D, Loria P, Cheng L, Kushner P, Agard D, Greene G. The structural basis of estrogen receptor/coactivator recognition and the antagonist of this alteration by tamoxifen. Cell 7:927-937, 1999.
19. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, O'Malley B. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922-1925, 1998.
20. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley B. The steroid receptor coactivator SRC-3 (pCIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 97:6379-6384, 2000.
21. Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG. Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci USA 97:13549-13554, 2000.
22. Smith CL, DeVera DG, Lamb DJ, Nawaz Z, Jiang YH, Beaudet AL, O'Malley B. Genetic ablation of the steroid receptor coactivatorubiquitin ligase, E6-AP, results in tissue-selective steroid hormone resistance and defects in reproduction. Mol Cell Biol 2:525-535, 2002.
23. Weigel N. Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319:657-667, 1996.
24. Knotts T, Orkiszewski R, Cook R, Edwards D, Weigel N. Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem 276:8475-8483, 2001.
25. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at set-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci 97:1032-1037, 2000.
26. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713, 1992.
27. Benhamou B, Garcia T, Lerouge T, Vergezac A, Gofflo D, Bigogne C, Chambon P, Gronemeyer H. A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 225:206-209, 1992.
28. DeMarzo AM, Onate SA, Nordeen SK, Edwards DP. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor. Biochemistry 31:10491-10501, 1992.
29. Skafar D. Differences in the binding mechanism of RU486 and progesterone to the progesterone receptor. Biochemistry 30:10829-10832, 1991.
30. Kuhnel B, El Ashry D, Edwards DP, Nordeen SK. Mapping contacts between unpurified human progesterone receptor and the hormone response element of mouse mammary tumor virus. DNA 10:703-713, 1989.
31. Chalepakis G, Arnemann J, Slater E, Bruller HJ, Gross B, Beato M. Differential gene activation by glucocorticoids and progestins through the hormone regulatory element of mouse mammary tumor virus. Cell 53:371-382, 1988.
32. Delabre K, Guiochon-Mantel A, Milgorm E. In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc Natl Acad Sci USA 90:4421-4425, 1993.
33. Gass EK, Leonhardt SA, Nordeen SK, Edwards DP. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to DNA in vitro and in vivo but have distinct effects on receptor conformation. Endocrinol 139:1905-1919, 1998.
34. Klein-Hitpass L, Cato ACB, Henderson D, Ryffel G. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucl Acids Res 19:1227-1234, 1991.
35. Onate SA, Tsai SY, Tsai M-J, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357, 1995.
36. El-Ashry D, Oñate SO. K. NS, Edwards DP. Human progesterone receptor complexed with the antagonist RU486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3:1545-1558, 1989.
37. Meyer M-E, Pornon A, Ji J, Bocquel M-T, Chambon P, Gronemeyer H. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J 9:3923-3932, 1990.
38. Allan GF, Leng X, Tsai SF, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-19520, 1992.
39. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 393:392-396, 1998.
40. Tanebaum D, Wang Y, Williams S, Sigler P. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 95:5998-6003, 1998.
41. Kraus WL, McInerney EM, Katzenellenbogen BS. Ligand-dependent, transcriptionally productive association of the amino- and carboxylterminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA 92:12314-12318, 1995.
42. He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994, 2000.
43. Tetel MJ, Giangrande PH, Leonhardt SA, McDonnell DP, Edwards DP. Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. Mol Endocrinol 13:910-924, 1999.
44. Bamberger A-M, Bamberger C, Gellersen B, Schulte HM. Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci USA 93:6169-6174, 1996.
45. Kalkhoven E, Wissink S, van der Saag PT, van der Burg B. Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor. J Biol Chem 271:6217-6224, 1996.
46. Christian M, Pohnke Y, Kempf R, Gellersen B, Brosens JJ. Functional association of PR and CCAAT/Enhancer-binding protein β isoforms: Promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. Mol Endocrinol 16:141-154, 2002.
47. Edwards DP, Leonhardt SA, Gass-Handel E. Novel mechanisms of progesterone antagonists and progesterone receptor. J Soc Gynecol Invest 7:22-24, 2000.
48. Edwards DP, Altmann M, DeMarzo A, Zhang Y, Weigel NL, Beck CA. Progesterone receptor and the mechanism of action of progesterone antagonists. J Steroid Biochem Mol Biol 53:449-458, 1995.
49. Leonhardt SA, Altmann M, Edwards DP. Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay. Mol Endocrinol 12:1914-1930, 1998.
50. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705, 1997.
51. Zhang X, Jeyakumar M, Petukhov S, Bagchi MK. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 12:513-524, 1998.
52. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18:1369-1378, 1998.
53. Wagner BL, Pollio G, Leonhardt SA, Wani MC, Lee DY-W, Imhof MO, Edwards DP, Cook CE, McDonnell DP. 16α-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc Natl Acad Sci USA 93:8739-8744, 1996.
54. Giangrande PH, Kimbrel ER, Edwards DP, McDonnell DP. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20:3102-3115, 2000.
55. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265, 1993.
56. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 90:4441-4445, 1993.
57. Sartorius CA, Tung L, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 268:9262-9266, 1993.
58. Rowan BG, Garrison N, Weigel N, O'Malley B. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 23:8720-8730, 2000.
59. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ, O'Malley B. The steroid coactivator, SRA, functions as a RNA and is present in an SRC-1 complex. Cell 1:17-27, 1999.
60. Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP. Jun dimerization protein-2 (JDP-2) functions as a progesterone receptor N-terminal domain coactivator. Mol Cell Biol 22: 5451-5466, 2002.
61. Katzenellenbogen BS, Katzenellenbogen JA. Defining the 'S' in SERMs. Science 295:2380-2381, 2002.
62. Mizutani T, Bhakta A, Kloosterboer HJ, Moudgil VK. Novel antiprogestins ORG 31806 and 31710: Interaction with mammalian progesterone receptor and DNA binding of antisteroid receptor complexes. J Steroid Biochem Mol Biol 42:695-704, 1992.
63. Kloosterboer HJ, Deckers GH, de Gooyer ME, Dijkema R, Orlemans EOM, Schoonen GEJ. Pharmacological properties of new selective antiprogestagen: Org 33628. Ann N Y Acad Sci 761:192-200, 1995.
64. Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffman J, Fritzemeier KH, Chwalisz K. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonists. J Med Chem 43:5010-5016, 2000.
65. Wagner BL, Pollio G, Giangrande P, Webster JC, Breslin M, Mais DE, Cook CE, Vedeckis WV, Cidlowski JA, McDonnell DP. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins. Endocrinol 140:1449-1458, 1999.
66. Pathirana C, Stein RB, Berger TS, Fenical W, Ianiro T, Mais DE, Torres A, Goldman ME. Nonsteroidal human progesterone receptor modulators from marine alga Cymopolia barbata. Mol Pharmacol 47:630-635, 1995.
67. Hamann LG, Farmer LJ, Johnson MG, Goldman ME, Mais DE, Davtian A, Bender SL, Jones TK. Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists. Ann NY Acad Sci 761:383-387, 1995.
68. Pooley CLF, Edwards JP, Goldman ME, Wang M-W, Marschke KB, Crombie DL, Jones TK. Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem 41:3461-3466, 1998.
69. Zhi L, Tegley CM, Pio B, West SJ, Marschke KB, Mais DE, Jones TK. Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines. Bioorgan Med Chem Lett 10:415-418, 2000.
70. Combs DW, Reese K, Phillips A. Nonsteroidal progesterone receptor ligands. 1. 3-Aryl-1-benzoyl-1,4,5,6-tetrahydropyridazines. J Med Chem 38:4878-4879, 1995.
71. Palmer S, Campen CA, Allan GF, Rybczynski P, Haynes-Johnson D, Hutchins A, Kraft P, Kiddoe M, Lai M-T, Lombardi E, Pedersen P, Hodgen G, Combs DW. Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity. J Steroid Biochem Mol Biol 75:33-42, 2000.
72. Tabata Y, Iizulka J, Masuda NT, Shinei R, Kurihara K-I, Okonogi T, Hoshiko S, Kurata Y. Fungal metabolites, PF1092 compounds and their derivatives, are nonsteroidal and selective progesterone receptor modulators. Eur J Pharm 430:159-165, 2001.
73. Neumann F, Graf K-J, Hasan SH, Schenck B, Steinbeck H. Central actions of antiandrogens. In: Martini L, Motta M, Eds. Androgens and Antiandrogens. New York: Raven Press, pp163-177, 1977.
74. Dukes M, Furr BJA, Hughes LR, Tucker H, Woodburn JR. Nonsteroidal progestins and antiprogestins related to flutamide. Steroids 65:725-731, 2000.